NCT02594813 Bleeding Rate After EGD and Colonoscopy in Patients Who Continue to Take Antithrombotic Agents
| NCT ID | NCT02594813 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Showa Inan General Hospital |
| Condition | Bleeding After GI Endoscopy |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2015-11 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2015-11 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The bleeding rate of both EGD (including biopsy) and colonoscopy (including biopsy, cold or hot snare polypectomy, or EMR) in patients who continue to take various antithrombotic drugs is studied prospectively. The immediate or delayed bleeding that requires hemostatic clipping or other endoscopic treatments is defined as the bleeding. Immediate bleeding requiring hemostatic clipping is defined as spurting or oozing which continued for more than 30 seconds. Delayed bleeding is defined as bleeding that requires the endoscopic treatment within 2 weeks after endoscopy. Prophylactic clipping is not performed after taking biopsy and doing polypectomy. Additionally, investigators evaluate the rate of injured submucosal arteries of the excised specimen when the bleeding occurs.
Eligibility Criteria
Inclusion Criteria: * Inclusion criteria is all patients who continue to take antithrombotic drugs and undergo EGD or colonoscopy Exclusion Criteria: * Patients who take prophylactic clipping after biopsy or polypectomy American Society of Anesthesiologists physical status of class IV or V
Contact & Investigator
Akira Horiuchi, MD
PRINCIPAL INVESTIGATOR
Showa Inan General Hospital
Frequently Asked Questions
Who can join the NCT02594813 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 90 Years, studying Bleeding After GI Endoscopy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02594813 currently recruiting?
Yes, NCT02594813 is actively recruiting participants. Contact the research team at horiuchi.akira@sihp.jp for enrollment information.
Where is the NCT02594813 trial being conducted?
This trial is being conducted at Komagane, Japan.
Who is sponsoring the NCT02594813 clinical trial?
NCT02594813 is sponsored by Showa Inan General Hospital. The principal investigator is Akira Horiuchi, MD at Showa Inan General Hospital. The trial plans to enroll 10,000 participants.